The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...
J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
HealthDay on MSN
FDA approves subcutaneous Rybrevant Faspro for EGFR-mutated non-small cell lung cancer
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Basel: Roche has received approval from the US Food and Drug Administration (FDA) for CD20xCD3 bispecific Lunsumio VELO ...
Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO ...
US FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma: Basel Tuesday, December 23, 2025, 13:00 Hrs [IST] Roche announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback